New Use for Amniofix
A new study came out this past month describing the use of micronized dehydrated human amniotic/chorionic membrane for the treatment of plantar fasciitis (Read Full Article). The authors describe the successful treatment of chronic cases of plantar fasciitis with dehydrated amniotic membrane and report that some patients experienced improvement in symptoms as early as one week after the treatment. These patients were reported to experience improvement in their symptoms throughout the eight week study period after the treatment.
We spoke to Dr. Sara Gould about this new treatment for plantar fasciitis. “This is an interesting study” she said, “There has already been literature published on the healing effect of the amniotic membrane for chronic wounds. The fact that it has applications for other chronic injuries is in line with those studies. “I think this study provides encouraging evidence for the use of amniotic membrane in chronic plantar fasciitis.” At Regional Orthopedics, Dr Gould is using Amniofix dehydrated human amniotic membrane for many of these applications. To see if you might benefit from Amniofix therapy, please contact Regional Orthopedics today.
- Chondrogenic Differentiation of Amniotic Fluid Stem Cells and Their Potential for Regenerative Therapy
- Chondrogenic potential of stem cells derived from amniotic fluid, adipose tissue, or bone marrow encapsulated in fibrin gels containing TGF-b3
- Stem Cell Therapy in a Caprine Model of Osteoarthritis
- The potential of intra-articular injection of chondrogenic-induced bone marrow stem cells to retard the progression of osteoarthritis in a sheep model
- Reduced Chondrogenic and Adipogenic Activity of Mesenchymal Stem Cells From Patients With Advanced Osteoarthritis
- Stem Cells for the Treatment of Osteoarthritis
- FAQ-Human Amniotic Membrane Allograft
- Stem Cell Therapy – AmnioFix
- The PURION Process
- Stem Cell Therapy – Video
- Sara Gould, MD, MPH, RMSK
This entry was posted on Wednesday, September 18th, 2013 at 12:33 am and is filed under Latest News. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.